| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $70.9M | — | +599.6% |
| SG&A Expense | $13.8M | — | +33.5% |
| Operating Income | -$84.7M | — | -313.8% |
| Net Income | -$78.9M | — | -338.6% |
| EPS (Basic) | -$3650.00 | — | +79.7% |
| EPS (Diluted) | -$3650.00 | — | +79.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $111.8M | -30.2% | +9.9% |
| Short-term Investments | $407.3M | +5.6% | — |
| Current Assets | $530.3M | -4.9% | — |
| Total Assets | $624.8M | -9.8% | — |
| Current Liabilities | $54.8M | +18.2% | — |
| Total Liabilities | $64.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$68.3M | — | -275.3% |
| Investing Cash Flow | $22.8M | — | +142.0% |
| Financing Cash Flow | -$3.0M | — | — |
| +14.4% |
| — |
| Stockholders' Equity | -$432.1M | -21.2% | -83.7% |